AU2017292754B2 - Tetrahydronaphthyridinepentanamide integrin antagonists - Google Patents

Tetrahydronaphthyridinepentanamide integrin antagonists Download PDF

Info

Publication number
AU2017292754B2
AU2017292754B2 AU2017292754A AU2017292754A AU2017292754B2 AU 2017292754 B2 AU2017292754 B2 AU 2017292754B2 AU 2017292754 A AU2017292754 A AU 2017292754A AU 2017292754 A AU2017292754 A AU 2017292754A AU 2017292754 B2 AU2017292754 B2 AU 2017292754B2
Authority
AU
Australia
Prior art keywords
naphthyridin
tetrahydro
compound according
mixture
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017292754A
Other languages
English (en)
Other versions
AU2017292754A1 (en
Inventor
Barry S. Coller
Marta Filizola
Michael Andrew Foley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Icahn School of Medicine at Mount Sinai
Original Assignee
Rockefeller University
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Icahn School of Medicine at Mount Sinai filed Critical Rockefeller University
Publication of AU2017292754A1 publication Critical patent/AU2017292754A1/en
Application granted granted Critical
Publication of AU2017292754B2 publication Critical patent/AU2017292754B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017292754A 2016-07-05 2017-07-05 Tetrahydronaphthyridinepentanamide integrin antagonists Active AU2017292754B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662358330P 2016-07-05 2016-07-05
US62/358,330 2016-07-05
US201662374234P 2016-08-12 2016-08-12
US62/374,234 2016-08-12
PCT/US2017/040657 WO2018009501A1 (en) 2016-07-05 2017-07-05 Tetrahydronaphthyridinepentanamide integrin antagonists

Publications (2)

Publication Number Publication Date
AU2017292754A1 AU2017292754A1 (en) 2019-01-24
AU2017292754B2 true AU2017292754B2 (en) 2021-06-17

Family

ID=60912284

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017292754A Active AU2017292754B2 (en) 2016-07-05 2017-07-05 Tetrahydronaphthyridinepentanamide integrin antagonists

Country Status (9)

Country Link
US (1) US11192889B2 (https=)
EP (1) EP3481814B1 (https=)
JP (1) JP2019524702A (https=)
KR (1) KR20190026001A (https=)
CN (1) CN109476632A (https=)
AU (1) AU2017292754B2 (https=)
CA (1) CA3029829A1 (https=)
MX (1) MX2019000043A (https=)
WO (1) WO2018009501A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509590A4 (en) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
FI3761980T3 (fi) * 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
AU2019318538B2 (en) 2018-08-08 2025-02-06 The General Hospital Corporation Polypeptide integrin antagonists
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
SI3844162T1 (sl) 2018-08-29 2025-06-30 Morphic Therapeutic, Inc. Zaviralci integrina alfa v beta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN114173803A (zh) * 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
TW202329973A (zh) * 2021-10-14 2023-08-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途
WO2024125634A1 (zh) * 2022-12-16 2024-06-20 西藏海思科制药有限公司 一种四氢萘啶类化合物及其在医药上的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
KR20010033248A (ko) * 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
CN1589145A (zh) * 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
FR2808798A1 (fr) 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
AU7793501A (en) * 2000-07-26 2002-02-05 Merck & Co Inc Alpha v integrin receptor antagonists
EP1389205B1 (en) * 2001-04-09 2005-12-21 Ortho-McNeil Pharmaceutical Research Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
JP2003277340A (ja) * 2002-03-22 2003-10-02 Toray Ind Inc 接着分子阻害剤及び新規アミノ酸誘導体
EP2456460A4 (en) 2009-07-24 2013-02-20 Univ California METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN
PT2953948T (pt) * 2013-02-07 2017-12-12 Scifluor Life Sciences Inc Antagonistas de integrina fluorada
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Whitman, D.B. et al, Bioorganic & Medicinal Chemistry Letters, 2004, 14, 4411-4415 *

Also Published As

Publication number Publication date
KR20190026001A (ko) 2019-03-12
EP3481814A4 (en) 2019-12-04
EP3481814A1 (en) 2019-05-15
WO2018009501A1 (en) 2018-01-11
EP3481814B1 (en) 2022-04-27
CA3029829A1 (en) 2018-01-11
JP2019524702A (ja) 2019-09-05
AU2017292754A1 (en) 2019-01-24
US11192889B2 (en) 2021-12-07
CN109476632A (zh) 2019-03-15
MX2019000043A (es) 2019-07-04
US20200181138A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
AU2017292754B2 (en) Tetrahydronaphthyridinepentanamide integrin antagonists
KR102866916B1 (ko) Lpa 수용체 길항제 및 이의 용도
ES2252775T3 (es) Antagonistas del receptor de vitronectina.
ES2856931T3 (es) Moduladores de ROR-gamma
JP4523281B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
EP2927231B1 (en) Imidazopyridine compounds
CA2896554C (en) Novel antiviral agents against hbv infection
JP2021193131A (ja) Ｒｏｒ−ガンマのモジュレータとしてのベンズイミダゾール誘導体
EP1441735B1 (en) N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US8030489B2 (en) Ornithine derivative
AU2004311749A1 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
TW201823208A (zh) N－醯基胺基酸化合物及其使用方法
JP6353072B2 (ja) カンナビノイド受容体アゴニストとしての５，６−二置換ピリジン−２−カルボキサミド
AU2012358359A1 (en) Non-systemic TGR5 agonists
JPWO2002053534A1 (ja) Ｖｌａ−４阻害薬
TWI598348B (zh) 雜環化合物及其用途
KR20080028929A (ko) Ｔｐｏ 모방체로서의 헤테로테트라시클릭 화합물
OA11341A (en) Vitronectin receptor antagonists.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)